The median whole-body tumor dose was 14.1 Gy in patients with PSA decline ≥ of 50% compared to patients with a PSA decline of less than 50% with a median dose of only 9.6 Gy, providing a rationale for individualized dosimetry during PSMA-RLT. Here, FOLH1 is linked to neoplasm.